Egetis Therapeutics AB (publ) (EGTX)

Nasdaq Stockholm | Biotech | Biotech / Orphan Drugs
Free
No email, no account, no signup.
Pulling latest news for Egetis Therapeutics AB (publ)…
Bull
Bear
Preliminary read — single AI model. The deep report cross-checks with four.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Biotech / Orphan Drugs
Market Cap
$276M
We're already tracking Egetis Therapeutics AB (publ) — here are the latest events we've registered

Recent News

  • In April 2026, the company completed a directed share issue of approximately 350 million SEK to fund the commercialization of Emcitate. Egetis also finalized its rolling NDA submission to the US FDA in January 2026, with a regulatory decision anticipated in the second half of 2026.
Want to know how this news affects Egetis Therapeutics AB (publ)? Order the analysis.
Order analysis – $4.99

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Egetis Therapeutics AB (publ) will be delivered in the same format.

Sample analyses in the same sector

Click to see what a complete analysis looks like.

Swedish Orphan Biovitrum AB (publ)
SOBI
HOLD
Liquidia Corporation
LQDA
BUY
Cereno Scientific B
CRNO B
HOLD
Dyne Therapeutics, Inc.
DYN
NEUTRAL
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
Egetis Therapeutics AB (publ) (EGTX)
Fresh analysis on demand
Order analysis – $4.99
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.